p53 mutations occur in most tumor types. Up to 87% occur 1 To whom correspondence should be addressed in exons 5-8 and 75% at G:C pairs (3) . The frequency and Email: yves.fradet@crhdq.ulaval.ca type of mutations, however, tend to be unique to each cancer Sequencing of p53 exons 5-8 was carried out on 51 initial (3) (4) (5) . The spectrum of mutations in tumors can provide clues superficial bladder tumors selected on the basis of high to their etiology; mutations may be caused by both endogenous grade and/or p53 overexpression (immunohistochemistry (spontaneous) biological processes and exogenous (environwithout antigen retrieval). Fourteen point mutations in 13 mental) carcinogens (6, 7) . Endogenous DNA alterations tumors and one 21 bp deletion in another tumor were include the spontaneous deamination of mC at mCpG dinucleidentified. In addition, a germ-line mutation corresponding otides, resulting in G:C→A:T transitions (7) . Carcinogens, on to a previously described polymorphism was detected in the other hand will often produce transversions; carcinogenexon 6, in two tumors. Mostly G→A transitions (10) were induced mutations occur preferentially on the non-transcribed found. Only three occurred at CpG sites, suggesting a major strand (3) . role for exogenous carcinogens in bladder tumorigenesis.
The half-life of mutated p53 is increased and, consequently, Immunostaining for p53 and MDM2, using antigen the protein reaches a level detectable by immunohistochemistry retrieval, was carried out on the same tumors. A correlation methods which thus provide the simplest way of detecting p53 was found between the percentage of p53-positive cells and mutations. However, this approach is not entirely reliable as the presence of p53 mutations (P ⍧ 0.005). No correlation some mutations will abolish p53 expression while the protein was found between overexpression of p53 and MDM2 in can be stabilized by mechanisms other than mutations. In this selected cohort of mostly high grade tumors. The addition, antigen retrieval approaches have so increased the presence of p53 mutations was also analyzed as a function sensitivity of detection that in some circumstances, normal of the smoking habits of the patients. A significant associunmutated p53 can be detected (8) . ation was found between the presence of p53 point
In bladder cancer, p53 overexpression has been associated mutations and the number of years of smoking (P ⍧ 0.043).
with a poor prognosis (9) (10) (11) (12) . In general, a good correlation All patients with tumors carrying missense or nonsense has been observed between overexpression of the protein and p53 mutations had smoked for ജ30 years and if former the presence of mutations (13) (14) (15) . However, the concordance smokers, had stopped for ഛ5 years. However, no correlation is not perfect suggesting that other mechanisms are also was found between the presence of p53 point mutations involved in the stabilization of this protein in bladder cancer. and the number of cigarettes smoked. The deletion mutation
The MDM2 protein is known to bind to p53, blocking its was the only one present in a tumor from a non-smoker.
transcription activation activity and targeting it for degradation The data suggest that duration of exposure to carcinogens (16) . mdm2 transcription is known to be activated by p53. Thus, is the most critical factor in p53 mutagenesis in bladder in normal conditions, an autoregulatory feedback mechanism cancer.
exists between the two proteins by which p53 limits its own activity. We would therefore expect that MDM2 overexpression precludes alterations of p53 such as mutations or Introduction overexpression. Consistent with this model, a study on p53 and mdm2 in soft tissue sarcomas found no tumors containing Mutations of the p53 tumor suppressor gene are present in alterations of both genes (17) . In non-small cell lung carcinapproximately 50% of all human cancers and are the most omas and in melanomas, MDM2 overexpression has been frequent genetic alteration known in human cancers. The p53 associated with p53 overexpression in the absence of p53 protein can also be inactivated by mechanisms other than mutations (18, 19 detected immunoreactivities for each protein mostly in different p53 acts as a transcription factor and is implicated in the subsets of tumors. regulation of the cell cycle and consequently in growth control
The pattern of p53 mutations has also been studied in bladder (1). The current view of the p53 role in the cell suggests that cancer. While many researchers have found a preponderance of it acts as the guardian of the genome, sensing damage or G→A transitions (3), others have found mostly transversions potential damage to the DNA and invoking a protective response either by blocking the cell cycle or by inducing (6, 23, 24 (29) . The p53-positive tumors were mostly of high grade and embedded sections using an antigen retrieval approach. Unmasking of both antigens was carried out in prewarmed 10 mM citrate buffer pH 6.0 by associated with shorter time to recurrence. A detailed history microwave treatment for 17 min at full power in a 900 W microwave oven of smoking habits is available for these patients and it was for p53 and for 5 min in a pressure-cooker in the microwave oven for MDM2.
observed that the smokers and past smokers presented a higher possible mechanisms of p53 overexpression.
Statistical analysis
The relation between p53 overexpression and the presence of mutations and
Materials and methods
between p53 and MDM2 overexpression was analyzed by the χ 2 test. Correlation between the presence of p53 mutations and cigarette smoking Tumors habits was analyzed by the Wilcoxon rank sum test as the distribution of Fifty-one bladder tumor patients were selected from a previously described values was not normal. All reported P-values are two-sided. cohort of patients with initial superficial tumors (29 T1, 21 TA, one undefined TA or T1) (30) . For each patient, snap frozen and formalin-fixed tumoral tissue was available. As a correlation of p53 overexpression with high grade Results was observed in most studies, we selected for sequencing all the grade III tumors for which we had frozen tissue (36 tumors). We also included in the DNA sequencing study all the grade I (two tumors) and II (13 tumors) tumors which stained Sequencing of p53 exons 5-8 was carried out on 51 superficial positively with a polyclonal anti-p53 in a previous study (29 The cigarette smoking history was obtained at the time of initial diagnosis, found were mostly transitions, with a marked strand bias: 10 using a standardized questionnaire. Patients were classified as current smokers, G→A, three A→G and one C→T. Three mutations occurred at past smokers or non-smokers. Information gathered included age at which smoking was initiated, time since stopping, as well as number of cigarettes CpG sites: codons 175 (patients 2 and 3) and 248 (patient 9). smoked per day during the last week and during the last year of smoking.
Only two transversions were identified: G→C (patient 12) and DNA extraction A→T (patient 16). Three silent mutations were found. Two Genomic DNA was prepared from tumor specimens by proteinase K digestion occurred at codon 213 in exon 6 (patients 6 and 7) and correspond of frozen 20 µm tissue sections or cell suspension as described previously to a previously reported rare polymorphism (33). Sequencing (31) . Blood leukocyte DNA was prepared from 200 µl whole blood also by of blood leukocyte DNA confirmed that these were germ line proteinase K digestion (32). DNA concentrations were determined by the mutations. The other silent mutation occurred at codon 287 in fluorometric diaminobenzoic acid assay (DABA). exon 8 (patient 15) and was associated with another mutation at DNA sequencing codon 285. It thus appears to represent a case of multiple Genomic DNA was amplified by nested PCR using the p53-specific primers mutations in the presumed hot spot for p53 mutations in bladder shown in Table I transition  80  20  10  T1  3  8  266  GGA→GAA  G→A  gly→glu  transition  75  20  11  T1  2  8  278  CCT→TCT  C→T  pro→ser  transition  5  5  12  T1  3  8  280  AGA→ACA  G→C  a r g →thr  transversion  15  5  13  T1  3  8  285  GAG→AAG  G→A  glu→lys  transition  70  5  14  TA  3  8  285  GAG→AAG  G→A  glu→lys  transition  75  40  15  TA  3  8  285  GAG→AAG  G→A  glu→lys of p53-positive cells and the presence of p53 mutations by χ 2 analysis (P ϭ 0.003) (Table III) . No mutants were found in tumors with no positive cells. Three tumors (17%) with 0.5-5% Ͼ5% p53-positive cells carried a p53 mutation while eight tumors (57%) with Ͼ20% p53-positive cells carried a p53 mutap53-positive cells carried a p53 point mutation. One of these was a stop mutation (patient 16). Eleven tumors (55%) with tion. This observation thus suggests a threshold of Ͼ5% positive cells, under these conditions, for defining a p53-positive tumor. Despite the correlation observed, two p53 mutants (other than the stop mutant) were found in the ഛ5% category while nine tumors in which no p53 mutations were found fell in the Ͼ5% larly puzzling situation occurred in patients 13, 14 and 15 who all carried the same mutation (G→A) in codon 285 (glu→lys) in their bladder tumor. Tumors 13 and 14 overexpressed p53 as There is a statistically significant correlation between the presence of p53 point mutations and the number of years of smoking expected while in tumor 15, only 1-2% of cells were p53 positive. This last tumor was the previously mentioned double mutant.
( Table VI) . Patients without p53 mutations in their tumors had smoked for a median time of 34.5 years (0-66 years) while However, the second mutation being silent, it cannot account for the absence of expression. This suggests that other damage exists patients with p53 point mutations had smoked for a median time of 49.5 years (30-67 years). Past smokers with a wild-type p53 elsewhere on the p53 gene or pathway.
In that perspective, we carried out MDM2 staining on the tumor had stopped smoking for a median time of 15 years (0.2-36 years) compared with only 3 years (0.2-5 years) for those same tumors (Tables II and IV) . Twenty-six of 51 tumors were MDM2 positive (ജ20% stained nuclei) (20). Using the previwith a p53 point mutation (Table V) . Also all patients with p53 point mutations had smoked more than 200 000 cigarettes before ously defined threshold of Ͼ5% positive cells for p53, we attempted to correlate p53 and MDM2 staining using the χ 2 test their first tumor event (Figure 1 ). However, no significant association was found between the presence of p53 mutations and the (Table IV) . No correlation was found. Ten tumors were found to express both antigens; of these, five (50%) carried a p53 mutanumber of cigarettes smoked, as the five heaviest smokers (more than 600 000 cigarettes) carried no p53 mutations in their tumor. tion. Ten p53-positive tumors were MDM2 negative; of these, six (60%) carried a p53 mutation. We detected no p53 mutation Three of these heavy smokers had stopped smoking for Ͼ5 years (for 6, 8 and 15 years, respectively) while the other two were in nine of these p53-positive tumors; of these nine tumors five overexpressed MDM2. Approximately 50% of the p53-negative current smokers, having smoked for 35 and 61 years, respectively. tumors overexpressed MDM2 (16/31) .
No significant association could be made between p53 p53 mutations as a function of cigarette smoking overexpression and smoking habits though only 7/26 (27%) of Complete information on smoking habits was available for 46 tumors from non-smokers and long-time past smokers (Ͼ5 patients while partial information was available for the years) overexpressed p53 compared with 12/24 (50%) in tumors remaining five. We could thus analyze the presence of p53 from the smokers and short time non-smokers (ഛ5 years). The mutations in relation to the smoking habits of the patients. With bladder tumor carrying the deletion mutation is included among the exception of the deletion mutation which was found in a the tumors from non-smokers overexpressing p53. tumor from a non-smoker, all other p53 mutations were found in tumors from current or past smokers. When patients were Discussion classified according to their cigarette smoking status, all patients with a p53 mutation in their bladder tumor (with the exception In this study, we have analyzed the presence of p53 mutations in a group of mostly high grade superficial bladder tumors, of the deletion mutation) were found to have smoked for ജ30 years or, if past smokers, had stopped smoking for ഛ5 years both by immunohistochemistry and by DNA sequencing. A significant association between the presence of p53 mutations (Tables V and VI) . On the other hand, all patients with wild-type p53-tumors were non-smokers or had quit smoking for Ͼ5 years. and p53 overexpression was observed when using antigen retrieval and monoclonal antibody 1801. In our previous study correlation could be made between the presence of p53 point mutations and the number of years of smoking. In addition,we (29) using a rabbit polyclonal primary antibody, and no antigen found no p53 mutations in bladder tumors from past smokers retrieval, although more mutants were found in the p53-positive who quit smoking for Ͼ5 years. These observations suggest tumors (8/27, 30%) than in the p53-negative ones (3/17, 17%) that time of exposure to carcinogens is a critical factor in p53 the difference was not statistically significant. In addition, under mutagenesis in bladder cancer and that p53 mutations are a late those conditions, patient 16's tumor presenting a stop codon at event in bladder carcinogenesis. Note that a study of smokingposition 305 was p53-positive. However, the truncated protein related carcinogen-DNA adducts in biopsies from human urinderived from such a mutant p53 gene could not possibly be ary bladders detected no difference in the levels of these adducts nuclear as it lacks the nuclear localization domain encoded by in the urinary bladders of non-smokers and past smokers with at codons 316-325 (35). In the conditions used in the present study, least 5 years abstinence (38) . In head and neck cancers, no this tumor contained Ͻ5% p53-positive cells. The correlation significant difference in the presence of p53 mutations among between p53 mutations and protein accumulation was thus better smokers and former smokers was found suggesting that, contrary with the use of the monoclonal antibody 1801 than the polyclonal to what is seen in bladder cancer, p53 mutations in these tumors antibody that we used in the past. To our knowledge, such a are an early event (7). comparative study has not been reported previously although
On the other hand, we could not demonstrate an association the 1801 monoclonal antibody has been reported to better predict between the presence of p53 point mutations and the total number survival than the polyclonal CM1 antibody (36) . Even with the of cigarettes smoked because, surprisingly, no p53 mutations monoclonal anti-p53, however, we observed p53 overexpression were detected in tumors from the heaviest smokers: more than in the absence of detectable mutations. This overexpression 600 000 total cigarettes smoked or 50-75 cigarettes per day could result from a defective MDM2 as it is known that by (Figure 1) . However, when we examined the period over which binding to the p53 protein, MDM2 targets it for degradation and these patients smoked, we found it varied considerably, between that the auto-regulation feedback mechanism existing between 22 and 61 years. Moreover, three of these patients had quit the two proteins help maintain their level. We found no correlasmoking for Ͼ5 years. Thus, the time of exposure again appears tion between the expression of the two proteins in this group of to be the critical element in p53 mutagenesis in bladder cancer, high grade tumors and thus cannot conclude that MDM2 plays even more so than the number of cigarettes smoked. At least one a role in p53 overexpression in tumors without p53 mutations. study has reported a link between cigarette smoking and the However, an immunohistochemical study of p53 and MDM2 presence of double mutations in p53 (23) . We found only one expression on a larger group of tumors from the same cohort such double mutation in our population of tumors which occurred found a correlation between expression of these two proteins but in codons 285 and 287, in the bladder tumor mutation hotspot, only in low grade tumors (37) . In that same study, it was noted where Spruck et al. (23) found three of their five double mutants. that p21 was less frequently expressed in tumors carrying a
We also found a 21 bp deletion in one tumor that is most probably mutated p53 gene. As only exons 5-8 were sequenced, it is explained by a replication error, due to the presence of direct possible that mutations lie elsewhere on the gene as it has been repeats. It was the only mutation found in a non-smoking patient. reported that in bladder cancer, up to 28% of mutations may lie It has recently been suggested that cigarette smoking increases outside of these exons (3). Thus, while immunohistochemistry the risk of recurrence of bladder cancer through its effect on p53 using an antigen retrieval technique and a monoclonal antibody (39), a hypothesis supported by our data showing statistical remains a simple and efficient way of detecting p53 mutations, correlation between p53 mutation and the number of years of it is clearly not capable of detecting all such mutations. cigarette smoking in a group of high-grade superficial bladder The pattern of point mutations (excluding the germline tumors. Moreover, in the cohort of patients from which these mutations) found in this study is remarkably homogeneous, tumors were selected, current smokers presented a higher proporwith 10/14 (71%) being G→A transitions. Of these, only three tion of recurrence than non-smokers (57 versus 47%) while occurred at CpG sites. A predominance of G→A transitions has p53 overexpression (by polyclonal antibody) was significantly been reported in other studies though usually at a lower frequency associated with earlier recurrence (30) . Taken together these (3). It probably reflects the homogeneity of our population of data suggest that superficial bladder tumor patients who smoke low stage initial tumors. The pattern of mutations and the strand cigarettes increase their risk of mutating p53 and of experiencing bias observed are compatible with the action of carcinogens such a recurrence or progression as was recently suggested by a as nitrosamines and thus with a tobacco-related disease (3). A retrospective study on disease outcome according to smoking predominance of G→A transitions has also been described in status in bladder cancer patients (40). Cessation of cigarette oesophagus and head and neck cancers, also related to tobacco smoking after the initial diagnosis of superficial bladder tumors smoking. In lung cancer, on the other hand, mostly G→T transmay perhaps have an impact on the outcome of the disease. As versions are reported, suggesting the action of distinct carcinothe correlation of p53 overexpression with smoking habit is not gens. These carcinogens could differ in solubility, nitrosamines as good as with the presence of DNA mutations, we can speculate being soluble while other inhaled products might not be. Such a that the mechanisms of inducing p53, other than through DNA hypothesis has been suggested for explaining different patterns mutation, are not related to cigarette smoking. In that same of p53 mutations between cancers of the oral cavity compared cohort of patients, we also observed a significant correlation with laryngeal and pharyngeal cancers (3) .
between the presence of chromosome 9 anomalies in bladder We hypothesized that in early tumors such as those analyzed tumors and recurrence. However, in that study, patients with here an association between smoking habits and the presence of a smoking history had a similar frequency of chromosome 9 p53 mutations would be easier to demonstrate as there would anomalies as non-smokers (41). have been less time for genetic damages to accumulate. Analysing the presence of p53 mutations in relation to the smokingthe manuscript. This work was supported by the National Cancer Institute of 20. Lianes,P., Orlow,I., Zhang,Z.-F., Oliva,M.R., Sarkis,A.S., Reuter,V.E. and Cordon-Cardo,C. 
